Trademagazin > News and articles > Company and Personal News > U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.
Related news
Róbert Zsigó: medicines will be cheaper
Medicines will be cheaper – the Parliamentary State Secretary of…
Read more >Are the drug and dietary supplement vending machines coming?
The soon-to-be widely available medicine vending machines, which are currently…
Read more >Medicines, yes, but we don’t look for healing on the Internet
In the case of a health complaint they have not…
Read more >
More related news >
Related news
Media Markt and Saturn may fall into Chinese hands
One of Europe’s best-known electronics store chains could have a…
Read more >LVMH’s six-month profit falls 22 percent, revenue falls 4 percent
LVMH Moët Hennessy Louis Vuitton SA, the world’s largest luxury…
Read more >Consumer Protection Authority: Family Frost recalled quick-frozen potato croquettes
Family Frost Ltd. has recalled pre-baked, quick-frozen potato croquettes due…
Read more >